Kyowa Hakko Kirin U.S. Subsidiary Licenses Antibody Technology
This article was originally published in PharmAsia News
Executive Summary
Japan's Kyowa Hakko Kirin subsidiary in the United States has licensed the technology behind its Potelligent technology to another U.S. firm for mass-producing antibodies